Ampoule production plant completed in May… Building a production base with research and education collaboration to strengthen global healthcare hub status
[by Kang, In Hyo] DongKoo Bio&Pharma announced on September 3 that it had signed a strategic Memorandum of Understanding (MOU) with the Mongolian National University of Medical Sciences (MNUMS) in Ulaanbaatar, Mongolia, on August 29, encompassing collaboration across the entire medical and pharmaceutical sectors. This agreement is regarded as a significant milestone for DongKoo Bio&Pharma in its efforts to establish a strong foothold in the Mongolian pharmaceutical and medical market while reinforcing its foundation for global expansion.
Under the agreement, the two parties intend to collaborate in various areas, including joint research in stem cell and regenerative medicine, new drug development and biopharmaceutical commercialization, the exploration of novel treatment technologies, professional medical training and personnel exchange programs, as well as the co-organization of academic seminars, workshops, and symposiums. In particular, through the joint implementation of projects aimed at strengthening 바카라 토토 사이트's public healthcare system, the partnership is expected to make a significant contribution to the advancement of country’s healthcare infrastructure.
Through this MOU, DongKoo Bio&Pharma has established a long-term collaboration framework that extends beyond the simple supply of products to encompass research and education. The company noted that this initiative is expected not only to improve the quality of healthcare services in 바카라 토토 사이트 but also to enhance the research capabilities of both Korea and 바카라 토토 사이트.
DongKoo Bio&Pharma had earlier formed a joint venture, ‘MDM (Munkhiin-DongKoo-MEIC),’ in partnership with the 바카라 토토 사이트n pharmaceutical company Munkhiin Tun LLC and the distributor MEIC, and in May completed the construction of an ‘ampoule manufacturing plant’ in Ulaanbaatar, 바카라 토토 사이트. Notably, this plant represents 바카라 토토 사이트's first foreign-invested pharmaceutical manufacturing site, established through a combination of technology transfer and joint investment.
The facility will initially prioritize supplying the domestic 바카라 토토 사이트n market, while gradually seeking Korean Good Manufacturing Practice (GMP) certification to position itself as an export hub targeting selected African nations, Commonwealth of Independent States (CIS) members, and Southeast Asian (ASEAN) countries. The company is also considering the reimportation of certain products back into Korea.
The MOU and the completion of the manufacturing plant hold considerable significance for DongKoo Bio&Pharma, positioning 바카라 토토 사이트 as a strategic gateway for global expansion through the establishment of an integrated framework of production, research, and education. Given 바카라 토토 사이트’s high dependence on pharmaceutical imports and the growing trust in Korean pharmaceutical products, the combination of localized manufacturing capacity and collaborative research is anticipated to further consolidate the company’s market leadership over the long term.
"Our partnership with the 바카라 토토 사이트n National University of Medical Sciences establishes a new model for our company, one that goes beyond the simple production and sale of products in 바카라 토토 사이트. It encompasses pharmaceutical research, medical workforce training, and public health improvement. Through this initiative, we aim to broaden our global healthcare collaborations and further strengthen our credibility in the international market," said Cho Yong-joon, CEO of DongKoo Bio&Pharma.